Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Aug;20(4):390-400.
doi: 10.1007/s12012-020-09566-6.

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism

Andrei Cristian Dan Gheorghe  1   2 , Ana Ciobanu  3   4 , Andreea Simona Hodorogea  1   2 , George Daniel Radavoi  1   5 , Viorel Jinga  1   5 , Ioan Tiberiu Nanea  1   2 , Gabriela Silvia Gheorghe  1   2
Affiliations
Observational Study

Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism

Andrei Cristian Dan Gheorghe et al. Cardiovasc Toxicol. 2020 Aug.

Abstract

We assessed the effects of antiandrogen therapy on ECG parameters of ventricular repolarization related to arrhythmic risk in 35 patients aged 70.3 ± 7 years with advanced prostate cancer treated with degarelix associated with enzalutamide (group A, 26 patients) or degarelix monotherapy (group B, 9 patients). We analyzed Fridericia corrected Q-T interval (QTc), Q-T dispersion (QTd), J-Tpeak interval (JTp), mean and maximum Tpeak-Tend interval (Tpe) and Tpe/QT ratio, Tpeak-Tend dispersion (Tped), index of cardio-electrophysiological balance (iCEB) from ECG tracings, and occurrence of ventricular premature beats (VPB) recorded by Holter ECG, before initiation of medication (M0) and after 6 months of treatment (M1). The groups had similar demographics except for a higher prevalence of prior myocardial infarction in group B (p = 0.01). All patients had low serum testosterone at M1. Baseline QTc, QTd, maxTpe/QT, meanTpe, maxTpe, Tped values were higher in B compared to A. They had a significant prolongation at M1 only in A. 20 patients in A and 6 in B had a 10% prolongation or decrease of iCEB (p = 0.66). In 5 patients, VPB severity increased from non-complex to complex: 3 in A and 2 in B (p = 0.31), but no sustained ventricular arrhythmia was registered. In conclusion, after 6 months of treatment, patients with hypogonadism on degarelix associated with enzalutamide had significant prolongation of QTc, QTd, maxTpe, meanTpe/QT, maxTpe/QT, Tped compared to patients on degarelix alone. The proportion of patients with 10% iCEB variation was similar between groups. There was no record of severe arrhythmias during the first 6 months of treatment.

Keywords: Degarelix; Enzalutamide; Hypogonadism; QT interval; Tpeak-tend wave interval.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Example of measurement of ECG repolarization parameters
Fig. 2
Fig. 2
Patient flowchart
Fig. 3
Fig. 3
Comparison of the amount of QTc and Tpe/QT ratio variation between treatment groups: group A = degarelix in association with enzalutamide; group B = degarelix in monotherapy
Fig. 4
Fig. 4
CTCAE grades of QTc prolongation in the studied groups
Fig. 5
Fig. 5
Proportion of patients with 10% iCEB variation in the studied groups between visits
See this image and copyright information in PMC

References

    1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211. - DOI - PubMed
    1. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care ontario clinical practice guideline. Journal of Clinical Oncology. 2014;32(30):3436–3448. doi: 10.1200/JCO.2013.54.8404. - DOI - PMC - PubMed
    1. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Influence of steroid hormones on ventricular repolarization. Pharmacology & Therapeutics. 2016;167:38–47. doi: 10.1016/j.pharmthera.2016.07.005. - DOI - PubMed
    1. Jonsson MKB, Vos MA, Duker G, Demolombe S, van Veen TAB. Gender disparity in cardiac electrophysiology: Implications for cardiac safety pharmacology. Pharmacology & Therapeutics. 2010;127(1):9–18. doi: 10.1016/j.pharmthera.2010.04.002. - DOI - PubMed
    1. Salem JE, Waintraub X, Courtillot C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018;138(1):110–113. doi: 10.1161/CIRCULATIONAHA.118.034282. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances